Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome
Abstract. Background:. Obesity and insulin resistance (IR) are common features of polycystic ovary syndrome (PCOS). Metformin (MET) increases insulin sensitivity, but it is associated with unsatisfactory weight loss. The glucagon-like peptide-1 receptor agonist exenatide has been shown to reduce wei...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2021-12-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000001712 |
| _version_ | 1818362750508728320 |
|---|---|
| author | Rui-Lin Ma Yan Deng Yan-Fang Wang Shi-Yang Zhu Xue-Song Ding Ai-Jun Sun Yan-Jie Yin Xiu-Yuan Hao |
| author_facet | Rui-Lin Ma Yan Deng Yan-Fang Wang Shi-Yang Zhu Xue-Song Ding Ai-Jun Sun Yan-Jie Yin Xiu-Yuan Hao |
| author_sort | Rui-Lin Ma |
| collection | DOAJ |
| description | Abstract. Background:. Obesity and insulin resistance (IR) are common features of polycystic ovary syndrome (PCOS). Metformin (MET) increases insulin sensitivity, but it is associated with unsatisfactory weight loss. The glucagon-like peptide-1 receptor agonist exenatide has been shown to reduce weight and IR in patients with diabetes. This study aimed to explore the therapeutic effects of exenatide once-weekly (QW) combined with MET on body weight, as well as metabolic and endocrinological parameters in overweight/obese women with PCOS.
Methods:. Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks. The primary outcomes were anthropometric changes associated with obesity, and the secondary outcomes included changes in reproductive hormone levels, glucose and lipid metabolism, and C-reactive protein.
Results:. Forty (80%) patients completed the study. COM therapy was superior to MET monotherapy in reducing weight (P = 0.045), body mass index (BMI) (P = 0.041), and waist circumference (P = 0.023). Patients in the COM group on an average lost 3.8 ± 2.4 kg compared with 2.1 ± 3.0 kg in the MET group. In the COM group, BMI and waist circumference decreased by 1.4 ± 0.87 kg/m2 and 4.63 ± 4.42 cm compared with 0.77 ± 1.17 kg/m2 and 1.72 ± 3.07 cm in the MET group, respectively. Moreover, levels of fasting glucose, oral glucose tolerance test (OGTT) 2-h glucose, and OGTT 2-h insulin were significantly lower with COM therapy than with MET (P < 0.050). Mild and moderate gastrointestinal reactions were the most common adverse events in both groups.
Conclusions:. COM therapy was more effective than MET alone in reducing body weight, BMI, and waist circumference, and improving insulin sensitivity in overweight/obese women with PCOS, with acceptable short-term side effects.
Trial registration:. ClinicalTrials.gov, NCT04029272. https://clinicaltrials.gov/ct2/show/NCT04029272 |
| first_indexed | 2024-12-13T21:37:33Z |
| format | Article |
| id | doaj.art-6a810a6cabaa4673bcc275ea92467c1a |
| institution | Directory Open Access Journal |
| issn | 0366-6999 2542-5641 |
| language | English |
| last_indexed | 2024-12-13T21:37:33Z |
| publishDate | 2021-12-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj.art-6a810a6cabaa4673bcc275ea92467c1a2022-12-21T23:30:39ZengWolters KluwerChinese Medical Journal0366-69992542-56412021-12-01134232882288910.1097/CM9.0000000000001712202112050-00017Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndromeRui-Lin Ma0Yan Deng1Yan-Fang Wang2Shi-Yang Zhu3Xue-Song Ding4Ai-Jun Sun5Yan-Jie Yin6Xiu-Yuan Hao7Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.Abstract. Background:. Obesity and insulin resistance (IR) are common features of polycystic ovary syndrome (PCOS). Metformin (MET) increases insulin sensitivity, but it is associated with unsatisfactory weight loss. The glucagon-like peptide-1 receptor agonist exenatide has been shown to reduce weight and IR in patients with diabetes. This study aimed to explore the therapeutic effects of exenatide once-weekly (QW) combined with MET on body weight, as well as metabolic and endocrinological parameters in overweight/obese women with PCOS. Methods:. Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks. The primary outcomes were anthropometric changes associated with obesity, and the secondary outcomes included changes in reproductive hormone levels, glucose and lipid metabolism, and C-reactive protein. Results:. Forty (80%) patients completed the study. COM therapy was superior to MET monotherapy in reducing weight (P = 0.045), body mass index (BMI) (P = 0.041), and waist circumference (P = 0.023). Patients in the COM group on an average lost 3.8 ± 2.4 kg compared with 2.1 ± 3.0 kg in the MET group. In the COM group, BMI and waist circumference decreased by 1.4 ± 0.87 kg/m2 and 4.63 ± 4.42 cm compared with 0.77 ± 1.17 kg/m2 and 1.72 ± 3.07 cm in the MET group, respectively. Moreover, levels of fasting glucose, oral glucose tolerance test (OGTT) 2-h glucose, and OGTT 2-h insulin were significantly lower with COM therapy than with MET (P < 0.050). Mild and moderate gastrointestinal reactions were the most common adverse events in both groups. Conclusions:. COM therapy was more effective than MET alone in reducing body weight, BMI, and waist circumference, and improving insulin sensitivity in overweight/obese women with PCOS, with acceptable short-term side effects. Trial registration:. ClinicalTrials.gov, NCT04029272. https://clinicaltrials.gov/ct2/show/NCT04029272http://journals.lww.com/10.1097/CM9.0000000000001712 |
| spellingShingle | Rui-Lin Ma Yan Deng Yan-Fang Wang Shi-Yang Zhu Xue-Song Ding Ai-Jun Sun Yan-Jie Yin Xiu-Yuan Hao Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome Chinese Medical Journal |
| title | Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome |
| title_full | Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome |
| title_fullStr | Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome |
| title_full_unstemmed | Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome |
| title_short | Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome |
| title_sort | short term combined treatment with exenatide and metformin for overweight obese women with polycystic ovary syndrome |
| url | http://journals.lww.com/10.1097/CM9.0000000000001712 |
| work_keys_str_mv | AT ruilinma shorttermcombinedtreatmentwithexenatideandmetforminforoverweightobesewomenwithpolycysticovarysyndrome AT yandeng shorttermcombinedtreatmentwithexenatideandmetforminforoverweightobesewomenwithpolycysticovarysyndrome AT yanfangwang shorttermcombinedtreatmentwithexenatideandmetforminforoverweightobesewomenwithpolycysticovarysyndrome AT shiyangzhu shorttermcombinedtreatmentwithexenatideandmetforminforoverweightobesewomenwithpolycysticovarysyndrome AT xuesongding shorttermcombinedtreatmentwithexenatideandmetforminforoverweightobesewomenwithpolycysticovarysyndrome AT aijunsun shorttermcombinedtreatmentwithexenatideandmetforminforoverweightobesewomenwithpolycysticovarysyndrome AT yanjieyin shorttermcombinedtreatmentwithexenatideandmetforminforoverweightobesewomenwithpolycysticovarysyndrome AT xiuyuanhao shorttermcombinedtreatmentwithexenatideandmetforminforoverweightobesewomenwithpolycysticovarysyndrome |